fig1

IRDiRC: 1000 new rare diseases treatments by 2027, identifying and bringing forward strategic actions

Figure 1. The three workstreams of strategic gap analysis, in which TSC members systematically explored the steps along the drug development process, identifying gaps and actions to be taken and who to involve in the process (A) and the combination of these assets with a direct suggestion list laying out the three pillars of the TSC strategy (B). These figures are based on Showeet.com template. TSC: Therapies Scientific Committee; IRDiRC: International Rare Diseases Research Consortium.

Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/